BRADBURY DANIEL

About BRADBURY DANIEL

Daniel M. Bradbury is an experienced life sciences executive best known for his long-standing governance role at Castle Biosciences, where he has served as a member of the board of directors since September 2012 and as chairman of the board since September 2014. He is also associated with Intercept Pharmaceuticals, Inc., where he has served as a board member, and with Equillium, Inc., which he co-founded and where he served as Executive Chairman. At Equillium, he also held the roles of Chief Executive Officer from June 2018 to January 2020 and President from March 2017 to June 2018. His operating background includes leading Amylin Pharmaceuticals as President, Chief Executive Officer and director from March 2007 until the company’s acquisition by Bristol-Myers Squibb in August 2012. Prior to that, he spent about ten years in marketing and sales at SmithKline Beecham Pharmaceuticals. Beyond board service, Bradbury founded BioBrit, LLC, a life sciences consulting and investment firm, where he has served as managing member since September 2012. His career reflects deep expertise in corporate strategy, commercial execution, and building value in biopharmaceutical businesses. He is particularly associated with guiding companies through growth phases, product commercialization, and strategic transactions. A notable achievement in his career was leading Amylin through its eventual acquisition, while also contributing to the governance of multiple publicly traded life sciences companies. He has served on boards across the sector, underscoring his experience in oversight, risk management, and capital-intensive decision-making in regulated markets. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.